{"entity":{"id":"nct05529940","kind":"trial","name":"NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)","aka":[],"tldr":"A phase 3 trial of fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Seoul National University Hospital, now recruiting.","summary":"NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) is a phase 3, randomised interventional study registered as NCT05529940 by Seoul National University Hospital, with a registry enrolment figure of 609 participants, started 2023-04-01 and due to reach its primary completion in 2024-12. Interventions recorded: Folfirinox. Conditions listed: Resectable Pancreatic Cancer; Neoadjuvant Chemotherapy; Effects of Chemotherapy. Primary outcome: 2-year survival rate. Pancreatic eligibility wording from the registry: \"Pancreatic ductal adenocarcinoma diagnosed by histological examination (histologic or cytopathological) D\". Sites: South Korea. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05529940","url":"https://clinicaltrials.gov/study/NCT05529940"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["folfirinox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05529940","phase":"3","setting":"Efficacy of Perioperative Versus Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: an International Multicenter Randomized Controlled Trial (NeoFOL-R Trial)","sponsor":"Seoul National University Hospital","enrolled":609,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05529940/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}